JUNAID Y MALEK M.D.
Prescription History 1487769162
Surgery - Vascular Surgery in Providence, RI

NPI Status: Active since August 20, 2006

Contact Information

195 COLLYER ST
SUITE 302
PROVIDENCE, RI
ZIP 02904
Phone: (401) 793-3236
Fax: (401) 793-5171

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JUNAID Y MALEK M.D., an active Vascular Surgery specialist practicing in Providence, RI. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 12 documented patient claims. Among these therapy options, the most frequently utilized medication is Cilostazol, which accounts for 12 claims alone.

Medication Index

No matching medications currently found on file.

Cilostazol

Generic Formulation: CilostazolSpecialty: General Surgery
Provider Metrics Summary
Total Claims 12
30-Day Fills 26.0
Days Supply 780
RI State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills65.7
Peer Average Days Supply1,959
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.6% less volume than the regional standard for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $517.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.10

State Avg Cost Per Claim

$30.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.

Therapeutic Applications

Cilostazol is used to improve the symptoms of a certain blood flow problem in the legs (intermittent claudication). Cilostazol can decrease the muscle pain/cramps that occur during exercise/walking. Claudication pain is caused by too little oxygen getting to the muscles. Cilostazol can increase blood flow and the amount of oxygen that gets to the muscles. Cilostazol is an antiplatelet drug and a vasodilator. It works by stopping blood cells called platelets from sticking together and prevents them from forming harmful clots. It also widens blood vessels in the legs. Cilostazol helps the blood to move more easily and keeps blood flowing smoothly in your body.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JUNAID Y MALEK M.D. provides transparency into local medical care patterns within Providence, RI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Vascular Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.